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Abstract
Background: Hospitals in sub-Saharan Africa are inundated with HIV-infected patients and tuberculosis (TB) is the
commonest opportunistic infection in this sub-group. Up to one third of TB-HIV co-infected patients fail to produce a
sputum sample (sputum scarce) and diagnosis is thus often delayed or missed. We investigated the sensitivity of urine-
based methods (Xpert MTB/RIF, LAM strip test and LAM ELISA) in such patients.
Methodology/Principal Findings: 281 HIV-infected hospitalised patients with clinically suspected TB provided a spot urine
sample. The reference standard was culture positivity for Mycobacterium tuberculosis on $1 sputum or extra-pulmonary
sample. MTB/RIF was performed using 1 ml of both unprocessed and, when possible, concentrated urine. Each
unconcentrated urine sample was also tested using the Clearview LAM ELISA and Alere LAM strip test. 42% (116/242) of
patients had culture-proven TB. 18% (20/54) were sputum scarce. In sputum-scarce patients, the sensitivity of urine MTB/RIF
and LAM ELISA was 40% (95%CI: 22–61) and 60% (95%CI: 39–78), respectively. Urine MTB/RIF specificity was 98% (95%CI:
95–100). Combined sensitivity of urine LAM ELISA and MTB/RIF was better than MTB/RIF alone [MTB/RIF and LAM: 70%
(95%CI: 48–85) vs. MTB/RIF: 40% (95%CI: 22–61), p = 0.03]. Significant predictors of urine MTB/RIF positivity were CD4,50
cells/ml (p = 0.001), elevated protein-to-creatinine ratio (p,0.001) and LAM ELISA positivity (p,0.001). Urine centrifugation
and pelleting significantly increased the sensitivity of MTB/RIF over unprocessed urine in paired samples [42% (95%CI: 26–
58) vs. 8% (95%CI: 0–16), p,0.001]. Urine MTB/RIF-generated CT values correlated poorly with markers of bacillary burden
(smear grade and time-to-positivity).
Conclusions/Significance: This preliminary study indicates that urine-based MTB/RIF, alone or in combination with LAM
antigen detection, may potentially aid the diagnosis of TB in HIV-infected patients with advanced immunosuppression
when sputum-based diagnosis is not possible. Concentration of urine prior to MTB/RIF-testing significantly improves
sensitivity.
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Introduction
In Africa, up to 65% of active tuberculosis (TB) cases are co-
infected with HIV [1]. TB-related mortality is highest in this
patient sub-group, and district-level hospitals are inundated with
patients with advanced immunosuppression. With advancing
HIV-related immunosuppression, the frequency of extra-pulmo-
nary (EPTB) and disseminated forms of TB disease increase [2,3],
sputum smear microscopy performance is reduced, and up to a
third of patients are unable to produce sputum for diagnostic
testing [4]. Diagnosis is therefore challenging and often delayed,
and post-mortem studies reveal a large burden of undiagnosed TB
in HIV-infected hospitalised patients [5,6,7]. Recent studies have
indicated that the rapid initiation of anti-TB treatment may
reduce mortality [8]. There is a clear need for new, accurate, and
rapid TB diagnostics that have utility in patients who cannot
produce sputum.
The Clearview TB LAM ELISA (Alere Medical innovations,
USA) detects LAM antigen in the urine and has recently evolved
into a new point-of-care lateral flow test (Alere Determine-TB
LAM Ag strip test) [9]. We recently found that this assay offered
the greatest benefit in hospitalised HIV co-infected patients with
advanced immunosuppression [4]. By contrast, the MTB/RIF
assay is a novel, automated molecular TB diagnostic able to detect
both the presence of Mycobacterium tuberculosis complex DNA and
rifampicin drug-resistance in less than two hours. This test has
been endorsed by the World Health Organization and is being
rolled out in South Africa as a frontline test for individuals with
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e39966
S
suspected TB [10,11]. Given the high accuracy of this test in
sputum samples (sensitivity and specificity of 90% and 99%) [12],
it represents a considerable advance over smear microscopy for the
diagnosis of pulmonary-TB. However, acquiring a diagnostic
sample remains a major hurdle in HIV-infected sputum scarce
patients suspected of having active TB. Sputum induction, using
ultrasonic nebulisation, may facilitate obtaining sputum, but this is
often unavailable in hospitals in resource-poor settings and
infection control is a concern. Tissue biopsies and aspirated
samples may be obtained from extra-pulmonary disease foci (e.g.
bone marrow and liver, pleural and pericardial fluid) but
specialised skill and equipment requirements limit the availability
and affordability in resource-poor settings. Urine is easily
obtainable from sputum scarce patients but there are few data
about the performance of newer diagnostic tests using urine [13].
We hypothesised that urine MTB/RIF may offer diagnostic
utility in patients where sputum-based diagnosis is not feasible.
The performance of this test specifically in sputum scarce patients
with HIV has not been previously evaluated using urine.
Methods
Study Population
The study population consisted of 335 prospectively recruited
adult patients from four hospitals (three district- and one tertiary-
level) between July 2009 and December 2010 in Cape Town,
South Africa. Patients were referred for study inclusion by
attending clinicians if the patient was suspected to have HIV-TB
co-infection. Only three patients, who refused consent, were
excluded from study enrolment. All other patients provided
written informed consent and the study was approved by the
University of Cape Town Faculty of Health Sciences Human
Research Ethics Committee. Clinical information documented for
enrolled patients included demographic information, past history
of TB, co-morbidity, symptoms and vital signs, HIV status and
renal function. A study outline is shown in Figure 1.
Diagnostic Sample Collection Handling
Consultant-led groups of attending clinicians with no associa-
tion to the study team decided on the timing and extent of
diagnostic work-up, commencement of empiric anti-TB treatment,
and final discharge from hospital. TB diagnostic work-up was not
standardised, but routine local hospital practice includes the
collection of two sputum samples in patients able to expectorate
and, if EPTB is suspected, the collection of 1–2 non-sputum
samples from clinically involved sites (e.g. fine needle aspirate of
lymph node, pleural fluid aspirate/biopsy, ascitic tap, lumbar
puncture, pericardial aspiration etc.). Further details of biological
samples collected for TB culture are provided in table 1. The local
reference laboratory processed all clinical specimens collected for
TB diagnosis. Fluorescence smear microscopy was performed on
NALC/NaOH processed sputum, which was also cultured using
the MGIT 960 liquid culture system (BD Diagnostics, USA). The
reference standard for definite-TB was liquid culture positivity for
M. tuberculosis.
Urine Sampling and LAM Methodology
All patients were required to give a spot urine sample (10–
30 ml) collected in a sterile container as soon as possible after
recruitment. A urine dipstick test (UriCHECK 9, RapiMed
Diagnostics, South Africa) was immediately performed to assess
for protein, blood and leucocytes, while the local reference
laboratory performed urinary protein and creatinine measure-
ments. Urine was frozen on the day of collection and stored at
220uC for later batched testing. Both the LAM ELISA and LAM
strip test (a single manufacturing lot#101102) were performed on
thawed urine according to the manufacturers’ instructions by
readers blinded to patient data. Detailed methodology for both
tests has been previously described [14]. Of note is the use of the
grade 2 cut-point and not the manufacturer’s suggested grade 1
cut-point for the LAM strip test. This cut-point optimises test
specificity and rule-in value [4] in hospitalised patients with HIV.
Urine MTB/RIF Methodology
All HIV-infected patients with culture positive TB had an
MTB/RIF performed using 1 ml of unprocessed, thawed urine
according to the manufacturers’ suggested procedure for sputum
samples [15]. In addition, a random sample of ,50% (62/126) of
culture negative non-TB patients had a urine MTB/RIF
performed. The MTB/RIF operator was blinded to the clinical
status of these patients. Briefly, the sample reagent was mixed at a
2:1 ratio with ,1 ml of urine. Two millilitres of the reagent
sample mix was transferred into an MTB/RIF assay cartridge and
inserted into the GeneXpert instrument [15]. Additionally, if the
MTB/RIF was negative using a 1 ml urine sample, a second
pelleted urine MTB/RIF was performed, where possible, using a
median (IQR) of 10 (5–10) ml urine. Urine was centrifuged at
3000 g for 15 minutes and the pellet re-suspended in 1 ml of sterile
phosphate-buffered saline. In culture-negative non-TB urine
samples used for MTB/RIF, pelleting of up to 10 mls was
performed where possible.
Statistical Analysis
Sensitivity and specificity measures for all diagnostic tests are
presented with 95% confidence intervals. Demographic, clinical
and microbiological characteristics of different patient sub-groups
were compared using x2 and Wilcoxon rank-sum test as
appropriate. Diagnostic sensitivity and specificity of individual
and/or combinations of tests was compared using the x2 and
Fisher’s exact tests, as appropriate. Logistic regression analysis was
used to identify predictors of urine MTB/RIF positivity (in all
patients and restricted to smear-negative and sputum scarce
patients). Spearman correlation (Rs) was used to evaluate
relationship between MTB/RIF-generated CT values and other
markers of bacillary load. All statistical tests were 2 sided at
a=0.05. STATA IC, version 10 (Stata Corp, Texas, USA) was
used for all statistical analyses. Study reporting and analysis were
consistent with the STARD criteria [16].
Results
Study Population and Proportion of Sputum Scarce
Patients
Figure 1 outlines the study population and test results. 93
patients were excluded from the primary analysis, leaving 242
patients with $1 sputum or non-sputum (or both) liquid culture
result. A further three patients had insufficient urine for MTB/
RIF, LAM ELISA and strip testing. Patient demographic and
clinical characteristics stratified by sputum smear status and urine
MTB/RIF results are shown in Table 1. Additionally, table 1
shows details of all biological samples undergoing mycobacterial
liquid culture. 48% (116/242) of included patients had culture-
positive TB from either a sputum (n= 68), non-sputum sample
(n = 26), or both (n= 22). Only 1/113 of culture positive patients
had a positive urinary m.tb culture.
17% (42/242) of all patients with valid culture results and 18%
(20/113) of culture positive were unable to produce sputum
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(sputum scarce). 52% (59/113) of TB patients were sputum smear-
positive.
Urine MTB/RIF Diagnostic Accuracy
Table 2 outlines the diagnostic accuracy of sputum smear
microscopy, urine MTB/RIF, LAM ELISA and LAM strip test in
all culture-positive patients stratified by CD4 cell count and
sputum scarce culture-positive patients only. Overall, MTB/RIF
had a sensitivity of 48% (95% CI: 39–57; 54/113), equivalent to
the overall sensitivities of sputum smear microscopy [52% (95%
CI: 43–61; 59/113)], urine LAM ELISA [58% (95% CI: 49–67;
65/112)] and LAM strip test (grade 2 cut-point) [48% (95% CI:
39–57; 55/113)]. Urine MTB/RIF sensitivity was higher in
patients with CD4#200 cells/ml vs. CD4$200 cells/ml [54%
(95% CI: 43–65; 42/78) vs. 31% (95% CI: 17–50; 8/26),
p = 0.04]. The highest urine MTB/RIF sensitivity of 61% (95%
CI: 48–73; 33/54) was in CD4#100 cells/ml. In sputum scarce,
non-sputum culture-positive patients, the sensitivity of urine
MTB/RIF was 40% (95%CI: 22–61; 8/20). Additionally, one of
the eight urine MTB/RIF positive patients was found to have
rifampicin-resistance and this was confirmed by phenotypic drug-
susceptibility testing. Urine MTB/RIF sensitivity was equivalent
to urine LAM ELISA and LAM strip test regardless of a patient’s
ability to produce sputum or sputum smear status. In sputum
smear-negative patients, the sensitivity of urine MTB/RIF was
39% (95%CI: 27–52; 21/54). The specificity of urine-based
MTB/RIF was 98% (95%CI: 95–100; 61/62), which was higher
than both the urine LAM ELISA and strip test [98% (95%CI: 95–
100) vs. 89% (95%CI: 81–97), p = 0.03].
The Effect of Urine Centrifugation on MTB/RIF
Performance
33% (38/116) and 41% (25/61) of culture positive and negative
patients respectively had sufficient archived urine available to
perform MTB/RIF using both 1 ml unprocessed and 2–10 ml
centrifuged and pelleted urine. The median (IQR) of urine used
for pelleting was 10 (5–10) ml. Comparing paired samples, the
sensitivity of urine MTB/RIF was higher using 2–10 ml centri-
fuged and pelleted urine than 1 ml unprocessed urine [42%
(95%CI: 26–58; 16/38) vs. 8% (95%CI: 0–16; 3/38), p,0.001].
Specificity of urine MTB/RIF was not affected by pelleting.
Pelleting allowed an additional 13 cases of TB to be detected, four
of which were from sputum scarce patients. Centrifugation and
pelleting of 6–10 mls produced a non-significant increase in
sensitivity compared with 2–5 mls [48% (95%CI: 29–67; 13/27)
vs. 28% (95%CI: 0–54; 3/11), p = 0.2]. No difference was noted in
Figure 1. Study flow diagram. 1Both sputum and non-sputum samples (e.g. blood, pleural or pericardial fluid) were collected by attending
clinicians for liquid TB culture. M.tb culture positive patients had at least one sputum or non-sputum sample liquid culture positive, while m.tb culture
negative patients had at least one (usually 2 or more) samples liquid culture negative *Results using a grade 2 cut-point for the urine LAM strip test
are shown.
doi:10.1371/journal.pone.0039966.g001
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the mean (SD) MTB/RIF internal positive control CT-value for
the MTB/RIF using 1 ml vs. 2–10 ml urine volumes [25.8 (1.4) vs.
25.9 (1.8), p = 0.4].
Combined Urine LAM ELISA and MTB/RIF
Figure 2 shows the proportions of sputum scarce TB patients
that were test-positive for both the urine LAM ELISA and
MTB/RIF or on only one of the two tests. Both urine MTB/RIF
and LAM ELISA detected six cases, while urine MTB/RIF and
LAM ELISA combined detected an additional two and six cases,
respectively. Table 2 shows that the combined sensitivity in
sputum scarce patients of urine LAM ELISA followed by MTB/
RIF was 70% (95% CI: 48–85; 14/20), compared to 40% (95%
CI: 22–61; 8/20) for urine MTB/RIF (p= 0.06), 60% (95% CI:
39–78; 12/20) for LAM ELISA (p = 0.5), and 45% (95%CI: 26–
66, 9/20) for LAM strip test (p = 0.1) alone. Overall, and in other
relevant patient sub-groups (sputum smear-negative/sputum
scarce, CD4#200 or #100 cells/ml), the combined sensitivity
of urine LAM ELISA and MTB/RIF was better than urine
MTB/RIF and LAM strip tests alone, but not urine LAM
ELISA alone.
Predictors of Urine MTB/RIF Test Positivity
Table 3 presents univariate associations of MTB/RIF positivity
in HIV-infected culture-positive patients stratified by sputum
smear status. CD4#50 cells/ml, protein/creatinine ratio
.0.03 g/l and urine LAM ELISA positivity were strong predictors
of urine MTB/RIF positivity. Additionally, patients with a
glomerular filtration rate (GFR) between 30–60 ml/min were
more likely to have a positive MTB/RIF [OR (95%CI): 3.0 (1.0–
8.3), p = 0.04]. Previous TB, smoking status, any TB symptom,
admission vital signs and urine dipstick abnormalities were not
associated with MTB/RIF positivity. In sputum smear/negative
and sputum scarce patients, only a CD4#50 and a protein/
creatinine ratio .0.03 g/l were strong predictors of urine MTB/
RIF positivity.
Table 1. Demographic, clinical and microbiological characteristics of m.tb culture positive and HIV-infected patients in the study
population stratified by sputum smear microscopy and urine MTB/RIF results.
Patient
characteristic(s)
$1 sputum or non-
sputum m.tb culture
positive
Sputum smear
positive
Sputum smear-
negative or sputum
scarce
Urine MTB/RIF
positive, m.tb
culture positive
Urine MTB/RIF
negative, m.tb
culture positive P-value{
(N=113) (N=59) (N=54) (N=54) (N=59)
n (%) n (%) n (%) n (%) n (%)
Age (years) 35 34 35 34 35 n/s
(median, IQR) (28–38) (27–38) (28–38) (28–39) (28–38)
Male 46 (41) 22 (37) 24 (44) 27 (50) 19 (32) n/s
CD4 cell count# 89 109 80 56* 142* *0.001
(median, IQR) (45–198) (50–215) (40–167) (33–134) (59–241)
Previous TB 32 (28) 19 (32) 13 (24) 13 (24) 19 (32) n/s
Current Smoker 25 (22) 15 (25) 10 (19) 13 (24) 12 (20) n/s
Clinical features
Cough .2 wks 96 (85) 52 (88) 43 (80) 46 (85) 50 (85) n/s
Night sweats 81 (72) 45 (76) 36 (67) 42 (78) 39 (66) n/s
Weight loss 102 (90) 53 (88) 50 (93) 52 (96)* 50 (85)* *0.003
Fever .38uC 29 (26) 19 (32) 10 (19) 16 (30) 13 (22) n/s
Clinical samples collected for TB culture
1 sputum sample 90 (80) 59 (100)* 34 (63)* 44 (82) 44 (78) *,0.001
$2 sputum samples 41 (36) 29 (49)* 12 (22)* 24 (44) 17 (29) *0.003
1 non-sputum sample 75 (67) 29 (49)* 46 (85)* 35 (65) 40 (68) *,0.001
$2 non-sputum sample 25 (22) 7 (12)* 18 (33)* 15 (28) 10 (17) *0.006
Microbiological TB diagnosis
16 sputum m.tb culture
positive
87 (77) 59 (100)* 28 (52)* 42 (78) 45 (76) *,0.001
16 non-sputum culture
m.tb positive
45 (40)1 14 (24)* 31 (57)* 24 (44) 21 (36) *,0.001
16both sputum & non-
sputum m.tb culture
positive
19 (17) 14 (24)* 5 (9)* 12 (22) 7 (12) *0.04
#9 patients did not have data CD4 count data.
1Includes the following m.tb culture positive samples: 7 blood cultures, 11 pleural fluid samples, 4 pericardial fluid samples, 3 ascitic fluid samples, 8 cerebrospinal fluid
(CSF) samples, 1 hip biopsy, 2 Lymph node biopsies, 5 fine needle aspirate, 1 gastric washing, 1 faeces and 2 pus swabs.
{P-values indicate significant differences between patient groups (marked with * to indicate comparison group) for demographic, clinical or microbiological
characteristics.
doi:10.1371/journal.pone.0039966.t001
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Urine MTB/RIF CT Values and Relationship to Other
Bacillary Burden Markers
In urine MTB/RIF positive patients, the mean (sd) CT -value
was 21.3 (13.8). Two-way scatter plots in figure 3 explore
correlations between urine CT -values and other markers of
bacillary burden. No correlations between urine MTB/RIF-
generated CT -values and mean urine LAM concentration
[spearman rho: 0.17, p = 025], LAM strip test grade [spearman
rho: 0.11, p = 0.4], sputum liquid culture time-to-positivity (TTP)
[spearman rho: 0.23, p = 0.15] and/or sputum smear microscopy
grade (in smear positive patients) [spearman rho: 0.04, p = 0.8]
were found. No correlation between urine CT -values and urine
culture TTP was possible as only 1/113 urine cultures was
positive. A weak, but significant inverse relationship between urine
CT -value and liquid culture TTP [spearman rho: 0.3, p = 0.03]
was noted. Additionally, urine MTB/RIF-generated CT-values
showed no significant correlation with CD4 T-cell count
[spearman rho: 0.27, p = 0.06].
Discussion
Sputum scarce, smear-negative and EPTB constitute a major
burden of undiagnosed TB in HIV co-infected hospitalised
patients [5]. Misdiagnosis and diagnostic delays lengthen hospital
stay and delay rapid treatment initiation, likely worsening TB-
related morbidity and mortality [8]. Urine-based diagnostics may
be particularly useful in these patients. The key findings of this
preliminary study are: i) urine MTB/RIF can detect TB, and
rifampicin resistance where applicable, in hospitalised HIV-
infected patients who cannot produce a sputum sample (the assay
detected 8 cases who would have been missed by conventional
sputum-based diagnostics i.e. 7% of culture positive TB cases); ii)
centrifugation and pelleting of 2–10 mls of urine significantly
Table 2. Diagnostic accuracy of sputum smear microscopy, urinary MTB/RIF, TB LAM ELISA, LAM strip test (grade 2 cut-point) and
clinically relevant combinations thereof in any sputum/non-sputum m.tb culture positive patients overall, in sputum scarce
patients only, and stratified by CD4 cell count{.
Diagnostic test(s)
All m.tb culture
positive
Only sputum-scarce
non-sputum m.tb
culture positive
HIV-infected
patients with
CD4 count
.200 cells/ml
HIV-infected
patients with
CD4 count
#200 cells/ml
Random sample of
m.tb culture negative
patients1
(N=113) (N=20) (N=26) (N=78) (N=62)
Sensitivity (%) Sensitivity (%) Sensitivity (%) Sensitivity (%) Specificity (%)
(95% CI) (95% CI) (95% CI) (95% CI) (95% CI)
n/N n/N n/N n/N n/N
Sputum smear microscopy 52#3 58#6 #7 50#8 100
(43–61) N/A (39–75) (39–61) (94–100)
59/113 15/26 39/78 62/62
Urine MTB/RIF 48#1 40#5 31#7 *1 54#9 *1 98#11
(39–57) (22–61) (17–50) (43–65) (95–100)
54/113 8/20 8/26 42/78 61/62
Urine LAM ELISA 58#4 60 27*2 69#8 *2 89#11
(49–67) (39–78) (14–46) (58–78) (81–97)
65/112 12/20 7/26 53/77 55/62
Urine LAM strip test
(grade 2 cut-point)
48#2 45 27#6 *3 56#10 *3 85
(39–57) (26–66) (14–46) (45–67) (77–94)
55/113 9/20 7/26 44/78 53/62
Urine LAM ELISA followed by
urine MTB/RIF (performed if
LAM ELISA negative)
68#1 #2 70#5 38*4 79#9 #10 *4 89
(60–77) (48–85) (20–57) (71–88) (81–97)
77/113 14/20 10/26 62/78 55/62
Urine LAM ELISA combined
with smear microscopy
74#3 #4 58*5 80*5 89
(65–82) N/A (39–77) (71–88) (81–97)
83/113 15/26 62/78 55/62
#Indicates p,0.05 for a comparison of the sensitivity between different tests (e.g. urine MTB/RIF vs. LAM strip test) or combinations thereof; specific p-value:
#1p = 0.002; #2p = 0.003; #3p = 0.001; #4p = 0.01; #5p = 0.06; #6p = 0.02; #7p = 0.05; #8p = 0.02; #9p,0.001; #10p = 0.002; #11p = 0.03.
*Indicates p,0.05 for a comparison of differences in sensitivity between CD4.200 and #200 groups for a specific test or combinations thereof; specific p-values:
*1p = 0.04; *2p,0.001; *3p = 0.009; *4p,0.001; *5p = 0.03; non-significant p-values not shown.
{9 culture positive patients with no available CD4 cell count results.
1Reference standard of culture was used which does not account for persons with culture-negative, clinical TB.
doi:10.1371/journal.pone.0039966.t002
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improved diagnostic yield vs. 1 ml unprocessed urine without
impacting the MTB/RIF indeterminate rate (almost a third of
patients diagnosed exclusively using centrifuged urine were
sputum scarce); iii) in sputum scarce, and other patient sub-
groups, the combination of urine LAM ELISA with urine MTB/
RIF improved sensitivity compared with urine MTB/RIF or LAM
strip tests alone; and iv) urine MTB/RIF positivity was strongly
associated with advanced immunosuppression and proteinuria
(suggesting a ‘leaky’ renal filtration mechanism).
Approximately 10–20% of HIV-infected patients with suspected
TB are unable to produce sputum for sputum-based diagnostics
[4,17]. An additional 50–70% will have smear-negative active TB
[18]. Sputum induction by ultrasonic nebulisation is an important
sampling adjunct but availability is very limited in resource-poor
settings, infection control is problematic, and sputum is still
unobtainable in ,10% of patients [17]. Thus, urine-based
diagnostics have the potential to offer incremental diagnostic yield
in this context. Urinary LAM, both as an ELISA-kit and recently
as a lateral flow strip test, is the most extensively evaluated urine-
based TB diagnostic [9,13,19]. It is most useful as a rule-in test in
HIV-infected persons with advanced immunosuppression
[4,20,21]. However, concerns about context-specific test specific-
ity, optimal cut-point selection (for the LAM strip test), and lack of
a drug-susceptibility read-out remain [4]. In this study we show the
overlapping, yet non-redundant, performance of urinary LAM
and MTB/RIF, and the improved overall diagnostic sensitivity of
using the tests in combination. There is limited information about
the performance of MTB/RIF in combination with adjunct
diagnostics [22].
There are limited published data about the performance of
MTB/RIF using urine samples. Hilleman et al., in a selected
laboratory cohort interrogating extra-pulmonary samples found
that MTB/RIF sensitivity was 100% in 6 culture-positive urine
samples with unknown HIV status [23], while Lawn et al, in HIV-
infected out-patients pre-ARV initiation, report the overall
sensitivity of urine MTB/RIF to be 19% [24]. By contrast, our
study focused on sputum scarce, hospitalised HIV-infected patients
where diagnosis is often delayed and challenging. It is likely that
HIV-infected patients’ with more advanced immunosuppression
accounted for the higher urine MTB/RIF sensitivity found in our
study.
We found a strong association between declining CD4 cell
count, LAM in the urine, proteinuria, and increasing urine MTB/
RIF positivity. This may reflect renal TB as part of disseminated
TB, increased bacillary burden in those with the most advanced
immunosuppression, a ‘leaky’ filtration mechanism or a combina-
tion of these. That a minority of the MTB/RIF-positive samples
were urine culture positive may simply reflect sampling error, the
limited volume sent for culture, or that there are several
mechanisms driving urine test positivity. Further molecular
biological and pathological studies are required to shed more
light on the underlying mechanisms.
The sensitivity of urine MTB/RIF was markedly improved by
the centrifugation and pelleting of , 2–10 mls urine. Indeed, the
concentration of a number of biological samples, such as
cerebrospinal and pleural fluid, has improved the performance
of traditional TB diagnostics [25]. However, concentration is also
Figure 2. Venn diagram showing the proportions of patients diagnosed by urine MTB/RIF and/or urine LAM ELISA in sputum scarce
m.tb culture positive patients. 6 patients were both urine MTB/RIF and LAM ELISA positive; 6 patients were urine LAM ELISA positive, but MTB/RIF
negative, while 2 patients were urine MTB/RIF positive, LAM ELISA negative.
doi:10.1371/journal.pone.0039966.g002
Table 3. Associates of MTB/RIF positivity in HIV-infected m.tb
culture positive patients stratified by smear status.
Patient characteristic (s) Odds ratio (95% CI) P-value
All patients (sputum smear positive and negative)
CD4#200 2.6 (1.0–6.7) 0.05
CD4#100 3.1 (1.4–6.8) 0.006
CD4#50 5.3 (2.0–13.9) 0.001
Protein/creatinine ratio .0.03 g/l 6.2 (2.3–17.1) ,0.001
Urea$7.1 mmol/l 1.6 (0.7–3.9) 0.3
GFR 30–60 ml/min* 3.0 (1.0–8.3) 0.04
Urine LAM ELISA 5.0 (2.2–11.4) ,0.001
Sputum smear-negative/scarce patients only
Age (years) 1.08 (1.00–1.16) 0.04
CD4#200 3.9 (0.7–20.2) 0.11
CD4#100 5.2 (1.4–19.4) 0.01
CD4#50 9.8 (2.4–38.8) 0.001
Protein/creatinine ratio .0.03 g/l 5.3 (1.3–21.8) 0.02
Urea$7.1 mmol/l 1.3 (0.3–4.8) 0.3
GFR 30–60 ml/min* 2.4 (0.4–14.0) 0.3
Urine LAM ELISA 2.6 (0.9–8.2) 0.1
*Glomerular filtration rate calculated using the modified Cochrane-Gault
equation.
doi:10.1371/journal.pone.0039966.t003
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believed to increase PCR inhibition and potentially the rate of
indeterminate test results. With only a single indeterminate test
result (on a 1 ml urine sample), and no change in the mean
internal positive control CT-value in centrifuged samples, we feel
that 10 mls of centrifuged and pelleted urine is optimal when using
MTB/RIF. The incremental yield of using volumes greater than
10 mls will require further evaluation.
Sputum-based MTB/RIF-generated CT-values have been
shown to strongly correlate with other markers of bacillary load,
such as liquid culture TTP and smear grade [15,26,27]. However,
we could show no such correlation with urine (either with urine or
sputum TTP and smear grade). This lack of correlation likely
reflects limited sample numbers, and the differential relationship
between urine bacillary load, renal abnormalities (renal TB,
glomerular dysfunction etc.) and total body bacillary load.
This preliminary study has important limitations. No sputum-
based MTB/RIF was performed in our study, thus we could not
compare performance between urine and sputum. However,
sputum samples were not stored in the parent study [4] and this
caveat is redundant in sputum scarce patients, which is the very
subgroup targeted by our study. Archived, frozen urine samples
were used for all TB diagnostic tests. This may have affected the
diagnostic performance of urine culture, but prior studies suggest
no impact on the performance of MTB/RIF [28] or LAM [19] in
this context.
In conclusion, this preliminary study indicates that urinary
MTB/RIF may aid the rapid diagnosis of TB in sputum scarce
HIV-infected patients with advanced immunosuppression. More-
over, urine centrifugation significantly improves sensitivity. Used
alone, or in combination with urine LAM, urine-based MTB/RIF
may potentially offer ,70% of HIV co-infected persons a TB
diagnosis with 24 hours of hospital admission. Finally, as
demonstrated in this study, the ability of MTB/RIF to offer
rifampicin drug susceptibility testing is an important advantage
over urine LAM. Further prospective studies in larger cohorts
using standardised TB diagnostic work-up are required to clarify
these findings.
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